Technical Analysis for XCUR - Exicure, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Centerline Cross | Bullish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Up 4 Days in a Row | Strength | 0.00% | |
Up 5 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
20 DMA Support | Bullish | 4.29% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 20 hours ago |
Up 5% | about 20 hours ago |
Up 3% | about 20 hours ago |
Up 2% | about 20 hours ago |
Possible Inside Day | about 21 hours ago |
Get a Trading Assistant
- Earnings date: 08/09/2024
Exicure, Inc. Description
Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Psoriasis Netherton Syndrome Oncology Applications Messenger RNA
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 6.0 |
52 Week Low | 1.44 |
Average Volume | 1,141,599 |
200-Day Moving Average | 2.53 |
50-Day Moving Average | 2.57 |
20-Day Moving Average | 2.63 |
10-Day Moving Average | 2.61 |
Average True Range | 0.38 |
RSI (14) | 61.09 |
ADX | 45.96 |
+DI | 37.13 |
-DI | 10.55 |
Chandelier Exit (Long, 3 ATRs) | 2.72 |
Chandelier Exit (Short, 3 ATRs) | 3.30 |
Upper Bollinger Bands | 3.09 |
Lower Bollinger Band | 2.16 |
Percent B (%b) | 1.07 |
BandWidth | 35.56 |
MACD Line | 0.03 |
MACD Signal Line | -0.02 |
MACD Histogram | 0.0465 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.85 | ||||
Resistance 3 (R3) | 3.80 | 3.53 | 3.74 | ||
Resistance 2 (R2) | 3.53 | 3.35 | 3.55 | 3.70 | |
Resistance 1 (R1) | 3.34 | 3.24 | 3.44 | 3.39 | 3.66 |
Pivot Point | 3.07 | 3.07 | 3.11 | 3.09 | 3.07 |
Support 1 (S1) | 2.88 | 2.89 | 2.98 | 2.93 | 2.66 |
Support 2 (S2) | 2.61 | 2.78 | 2.63 | 2.62 | |
Support 3 (S3) | 2.42 | 2.61 | 2.59 | ||
Support 4 (S4) | 2.47 |